Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 30 December 2011 | By Alexander Gaffney, RAC
Are class-wide risk evaluation and mitigation strategies (REMS) products the future of risk mitigation?
The US Food and Drug Administration (FDA) moved one step closer to making that a reality by approving a single, shared REMS system on Thursday that applies to all transmucosal immediate-release fentanyl (TIRF) products. The program, dubbed the TIRF REMS Access Program, is designed to limit the drug to appropriate populations and ensure safe usage by patients.
The program will also unify the currently-fragmented REMS systems that exist in the TIRF class of products, which include Abstral, Actiq, Fentora, Lazanda, Onsolis, and Meda B.
TIRF products contain fentanyl, which is an opioid pain reliever commonly used by patients who have sudden pain that is not managed by the use of other opioid medications.
The program will begin in March of 2012, at which time all users currently being served by TIRF REMS programs will be transferred to the unified system.
The FDA notes that the goal of the program is to ensure that:
FDA hopes that this new, unified REMS system will "reduce the burden on the healthcare system of having separate REMS programs in place for individual TIRF medicines."
FDA also notes that, "we are continuing work on another class REMS for the class of long-acting and extended-release opioids."
This could make the TIRF REMS Access Program a bell-weather case study for the FDA.
Tags: Class, Opioids, TIRF, Fentanyl, Latest News, REMS
Regulatory Focus newsletters
All the biggest regulatory news and happenings.